Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidation Cyclophosphamide + Bortezomib + Dexamethasone after Autologous Stem Cell Transplantation in Multiple Myeloma
KCT0001327Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, bortezomib, dexamethasone in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Jul 2014; status: completed.
02
Drugs
cyclophosphamidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0001327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001327.